On the public citation graph

https://doi.org/10.2139/ssrn.4656812

0 signed · 16 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cam4.413openalex-extracted
Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALK
inferredcites →https://doi.org/10.1007/s10555-008-9165-4openalex-extracted
Signal transduction by focal adhesion kinase in cancer
inferredcites →https://doi.org/10.1016/j.ctrv.2019.05.004openalex-extracted
Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma
inferredcites →https://doi.org/10.1016/j.ejca.2021.06.043openalex-extracted
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non–small-cell lung cancer: a multicenter study using targeted next-generation sequencing
inferredcites →https://doi.org/10.1016/j.hoc.2016.08.012openalex-extracted
Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1016/s0140-6736(16)32453-9openalex-extracted
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s0140-6736(18)30207-1openalex-extracted
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
inferredcites →https://doi.org/10.1021/acs.jmedchem.6b00487openalex-extracted
Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)
inferredcites →https://doi.org/10.1056/nejmoa0708857openalex-extracted
Sorafenib in Advanced Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1717002openalex-extracted
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1186/s13058-016-0694-4openalex-extracted
The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells
inferredcites →https://doi.org/10.1200/jco.2017.77.4794openalex-extracted
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.3390/cancers11081074openalex-extracted
The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
inferredcites →https://doi.org/10.3390/ijms222111718openalex-extracted
Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer
inferredcites →https://doi.org/10.3978/j.issn.2218-6751.2014.03.01openalex-extracted
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
inferredcites →https://doi.org/10.3978/j.issn.2218-6751.2014.08.01openalex-extracted
Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer.
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.